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Primary and Secondary Leiomyosarcoma
of the Oral and Perioral
Region—Clinicopathological and
Immunohistochemical Analysis of a Rare
Entity With a Review of the Literature
Anja Sch€utz, DDS,* Ralf Smeets, MD, DDS, PhD,y Oliver Driemel, MD, DDS, PhD,z
Samer George Hakim, MD, DDS, PhD,x Hartwig Kosmehl, MD, PhD,k
Henning Hanken, MD, DDS,{ and Andreas Kolk, MD, DDS, PhD#
Purpose: Leiomyosarcoma (LMS) rarely occurs in the head and neck region. These tumors present with
a wide range of clinical features, so the diagnosis is predicated on conventional microscopic findings
coupled with immunohistochemical analysis.
Patients and Methods: Clinical and histologic data of 7 patients with LMS of the head and neck were
recorded retrospectively. In addition to routine immunohistochemistry, staining for cell cycle regulator
proteins p16 and p21 was performed.
Results: Five LMSs (4 intraoral, 1 dermal cheek) occurred primarily in the oral and perioral region. Two
LMSs (parietal and sinonasal) were diagnosed as metastases originating from the uterus and pelvis. Treat-
ment of the primary LMSs consisted of radical tumor resection with clear margins. Distant metastases from
LMSs were irradiated or excised as palliative treatment. Three of 5 patients (60%) with primarily excised
LMS developed recurrence after an average of 7 months, with lung metastases occurring after 17 months.
In 1 patient, cervical lymph node metastases were detected after 10 months. Of all patients, 5 died after an
average survival period of 2.4 years. The mean survival period of the 5 patients with primary LMS of the
head and neck was 3.3 years. All tumors were positive for vimentin and a-smooth muscle actin, with 57%
of tumors showing positive nuclear expression of p16 and 71% of p21. Lack of p16 nuclear expression was
associated with a shorter mean survival time (1.3 vs 4.3 yr for p16 positivity).
Conclusion: Lung and cervical lymph node metastases often occur in LMS of the head and neck. Presur-
gical staging, including gynecologic examination, whole-body computed tomography, and sometimes
positron-emission or computed tomography, to rule out LMS metastasis is mandatory. Surgical resection
of the tumor should be given top priority. Lack of p16 reactivity may have a prognostic value for LMS
because it was related to a trend toward poorer survival.
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Leiomyosarcomas (LMSs) are rare tumors that arise
from smooth muscle cells of the myometrium, gastro-
intestinal tract, or retroperitoneum.1 They account for
7% of soft tissue sarcomas.2 LMSs are found predomi-
nantly in the uterus, gastrointestinal tract, or retroper-
itoneal space,3 whereas LMSs in the head and neck
region account for only 3%, most likely because of
the paucity of smooth muscle tissue.4-6 Fewer than
0.1% develop in the oral cavity.7 LMSs of the oral and
perioral region are divided further into 3 main sub-
groups: LMS of the oral soft tissue, LMS of the facial
skin, and LMS of the jawbone. Separate from these
are primary LMSs of the head and neck and metastases
originating from the female genitalia, predominantly
the uterus.8 LMSs of the head and neck are rare
tumors with various clinical and histopathologic ap-
pearances. Origins of the LMS of the head and neck
are probably in the arterial tunica media, ductus lin-
gualis, circumvallata papillae, and pluripotent mesen-
chymal cells.6 The most frequent sites are the
sinonasal tract (19%), the skin and soft tissue (16%),
and the esophagus (12%).6
The prognostic significance of the localization of
LMS in the head and neck region is unclear. Because
of the rare occurrence and poor prognosis of LMS,
existing systematic data are insufficient and evidence
of effective therapy is scarce. The new World Health
Organization classification indicates a poor prognosis
for primary LMS of the sinonasal tract and a variable
outcome of primary LMS of the larynx.1 The progno-
sis of LMS in the oral and maxillofacial region is also
poor, with a large percentage of recurrence and me-
tastasis.1,5 The estimated 5-year disease-specific sur-
vival rate (DSS) for primary oral LMS is 55%.1,2 The
respective 5-year DSS data of primary LMS of the
oral and perioral soft and hard tissues indicate a sur-
vival rate from 32% to 62%2,7,9 (Table 1),2,4,7,9-13
because LMS of the oral soft tissue has a better
prognosis than LMS infiltrating the jaws, which has
a significantly higher recurrence rate.1,2 The reason
for this difference may be easier follow-up treatment
of the soft tissue region, with the possibility of earlier
detection of an initial tumor recurrence than that of
the jawbone, which can be followed only by imaging
methods.
Diagnosis of these tumors is often challenging. Im-
munohistochemistry for vimentin, desmin, or a-
smooth muscle actin (ASMA) provides features of
smooth muscle cell differentiation, which is critical
for the diagnosis of LMS.14
Proto-oncogenes and suppressor oncogenes that
have contrary functions in cellular growth normally
regulate cellular proliferation. Apart from multiple
other changes, neoplastic development is character-
ized by a loss of cell cycle control. Proteins p16 and
p21 are cell cycle regulators that have been studied
in different human neoplasms, including uterine
smooth muscle tumors.15,16
By inactivating the cyclin-dependent kinase (CDK)
that phosphorylates the retinoblastoma protein, pro-
tein p16 acts as a CDK inhibitor that slows down the
progression of the cell cycle. Protein p21 is also a po-
tent CDK inhibitor and binds to and inhibits the activ-
ity of cyclin-CDK2 or -CDK1 complexes and thus
functions as a regulator of cell cycle progression at
the G1 phase.
The cell cycle regulators p16 and p21 are tightly
controlled by tumor suppressor protein p53,17 which
is often mutated and overexpressed in LMS.18,19 The
latter findings suggest a connection between tumor
progression and immunohistochemical expression
levels of p16 and p21. The overexpression of p16
appears to distinguish malignant LMSs from benign
leiomyomas.20 The aims of this retrospective study
were to document the clinical presentation, clinical
course, and treatment of the rare entity of primary
LMS of the oral cavity and to analyze the impact of
cell cycle proteins p16 and p21 as an adjunct to con-
ventional immunohistochemical criteria of LMS of
the head and neck region.
Patients and Methods
Clinical treatment, follow-up, and histologic data of
7 patients with primary LMS of the head and neck
were recorded after therapy. The out- and inpatient
medical records of the university clinics of oral and
maxillofacial surgery in Regensburg and L€ubeck, Ger-
many from 1996 through 2008were reviewed. Clinical
data were correlated with tumor grade, which was as-
sessed using the National Cancer Institute system.21
Owing to the retrospective nature of the study, it
was granted a written exemption of the institutional
review board standards of individual institutions by
the universities of Regensburg and L€ubeck. In addi-
tion, all patients signed an informed written consent
agreement allowing the use of follow-up data and his-
tologic specimens for research purposes.
The diagnosis of a distant metastasis of an occult pri-
mary tumor was excluded in 5 cases of primary LMS of
the head and neck region by a full gynecologic exam-
ination and whole-body computed tomography (CT)
or magnetic resonance imaging (MRI) at the time of ini-
tial diagnosis. An additional positron-emission tomo-
graphic or CT scan was performed in the primary
LMS cases when the CT or MRI findings were unclear




blocks from every patient were stained with
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Table 1. LITERATURE SURVEY OF EPIDEMIOLOGY, TREATMENT, AND CLINICAL COURSE OF PRIMARY LEIOMYOSARCOMA OF THE HEAD AND NECK REGION











6 (5 case reports +
1 own case)
5:1 18-62 mandible (6) OP (6), RT (1),
CT (2)
67 50 50% after 24-60 mo,y 33% !T




11 1.2:1 40 jaw bone (11) OP (10), RT (3),
CT (2)
NES 36 36% after 36 mo,y
36% !T after 12 mo,*
18 +T after 24 mo*
Dry et al10
(2000)
10 1:1.5 34 jaw bone (5), oral soft tissue (5) OP (9), RT (1), CT
(2), unknown (1)
20 33 50% after 20 mo,y
40% !T after 49 mo*
Ethunandan et al2
(2007)
64 1.3:1 43 jaw bone (38), oral soft
tissue (20), facial skin (6)
OP (60), RT (14),
CT (11)
34 35 5-yr DSS 55% total, 43%
with bone infiltration,
19% with metastasis
Izumi et al9 (1995) 60 1.4:1 42 jaw bone (27), maxillary sinus
(14), oral soft tissue (18),
fascial skin (1)
OP (55), RT (4), CT
(39), unknown (2)




20 4:1 65-70 jaw bone (8), skeleton bones (12) OP (18), RT (6),
CT (2)
NES 37 35% after 24 mo,y 45%
after 21 mo,* 20% NES
Montgomery et al4
(2002)
13 1.2:1 47 jaw bone (5), oral soft tissue (3)
fascial skin (2), neck muscles (2),
pharynx (1)
OP (9), unknown (4) 27 55 23% after 67 mo,y
38% !T after 50 mo,*
8% +T after 24 mo,*
31% NES
Vilos et al7 (2005) 50 1:1.3 44 jaw bone (34), oral soft tissue (15),
maxillary sinus (1)
OP (46), RT (14), CT
(13), unknown (4)
NES 32 5-yr DSS 62%
Present study 7 1:1.3 60 oral soft tissue (4), fascial skin (1),
distant metastasis (2)
OP (6), RT (2) 43 71 71% after 29 mo,y
29% !T after 67 mo*
Abbreviations: CT, chemotherapy; DSS, disease-specific survival rate in years; F, female; M, male; NES, not elsewhere specified; OP, operation with radical resection; RT, radiation
therapy; +T, with tumor; !T, without tumor.
* Alive.
y Died.







































hematoxylin and eosin. For immunohistochemical
markers vimentin, desmin, ASMA, and Ki-67, results
of routine immunohistochemistry were obtained.
Staining for cell cycle regulator proteins p16 and p21
also was performed with commercially available anti-
bodies against p16 (Mtm Laboratories, Germany) and
p21 (ScyTek, Zytomed Systems, Berlin, Germany).
The sources and dilutions of all primary antibodies
are presented in Table 2. For the negative control, rep-
resentative sections were incubated with normal rab-
bit serum (1:100; DAKO, Glostrup, Denmark) and
processed simultaneously as described earlier. Only
nuclear staining was considered a positive reaction
for p16 and p21. The evaluation of immunohistochem-
ical staining was performed semiquantitatively and
qualitatively by analyzing the percentage of positively
stained tumor cells in 5 representative high-power
fields, as explained later.22
Briefly, the percentage of tumor cells with positive
staining was estimated by counting 1,000 tumor cells.
The number of positively stained tumor cells was
scored on a scale of 0 to 4 (0, no tumor cells; 1, 10%
tumor cells; 2, 10% to 25% tumor cells; 3, 26% to
50% tumor cells; 4, 50% tumor cells). Nuclear staining
intensity was evaluated according to the intensity of
positive immunostaining as negative (!), weak (+),
moderate (++), or strong (+++).
Detection of the bound antibody was performed
with the ChemMate detection system (Dako Chem-
Mate detection system, Hamburg, Germany) (alkaline
phosphatase) and an immunostaining automatic ma-
chine (Dako Autostainer, Hamburg, Germany) accord-
ing to the manufacturers’ protocols (Table 2).
Results
CLINICAL AND FOLLOW-UP DATA
Seven patients (3 male and 4 female) with primary
LMS of the head and neck region were evaluated.
The average age was 60 years (25 to 93 yr). Five LMS
tumors (4 intraoral, 1 in dermal cheek) occurred
primarily in the oral and perioral region (Table 3,
Fig 1A-D). Two LMS tumors (parietal and sinonasal)
were diagnosed as distant metastases originating
from the uterus and pelvis. In these 2 cases, therapy
of the primary LMS consisted of surgical tumor resec-
tion with clear margins. In 3 cases, a selective neck dis-
section was performed, and 1 patient underwent
irradiation after surgery. Distant LMS metastases were
treated with palliative radiation or excised (Table 3).
Independent of the selected therapy, 3 of 5 patients
(60%) with primary LMS developed local recurrence
after an average of 7 months (3 to 10 mo); in addition,
lung metastases occurred after 17 months in all
patients. In 1 patient, cervical lymph node metas-
tases were detected 10 months after solitary tu-
mor resection.
Distant metastases in the head and neck region of
the LMS of the uterus and pelvis developed parietally
and ethmoidally and in the cavernous sinus and retro-
auricularly and in the median skullcap, respectively.
Furthermore, metastases occurred in the lung and sub-
mandibular gland (Table 3).
Five patients with metastases died after an average
survival time of 2.4 years (1.0 to 5.3 yr). Two patients
with primary LMS of the dermal cheek and the floor of
the mouth were still alive after the end of the maxi-
mum 6.5-year follow-up period of this study without
metastases or recurrence (4.7 and 6.5 yr, respectively;
Table 3).
The mean survival period of all patients was 3.3
years (1.0 to 6.5 yr). Because of the small sample,
the average survival period of the 5 patients with pri-
mary LMS of the head and neck was the same at 3.3
years (1.0 to 6.5 yr).
HISTOLOGY
All LMS cases in this research series were assessed
for tumor depth, presence of circumscribed versus
infiltrative tumor borders, mitotic counts per 10
high-power fields (5 sets counted), necrosis, nuclear
pleomorphism, vascular invasion, and the occur-
rence and environment of inflammatory compo-
nents. Routine hematoxylin and eosin–stained LMS
Table 2. PRIMARY ANTIBODIES USED IN THIS STUDY
Antibody Clone Producer Dilution Pretreatment
p16 E6H4 Mtm Laboratories — Peroxidase blocking system, pH 9
p21 DSC-60.2 Zytomed Systems 1:50 Target Retrieval Solution 1:10, pH 6.1
Vimentin V9 Dako 1:4,500 Target Retrieval Solution 1:10, pH 9
Desmin D33 Dako 1:200 Target Retrieval Solution 1:10, pH 9
ASMA 1A4.(1) Dako 1:300 Target Retrieval Solution 1:10, pH 9
Ki-67 MIB1 Dako 1:1,000 Target Retrieval Solution 1:10, pH 6.1
Abbreviation: ASMA, a-smooth muscle actin.
Sch€utz et al. Leimyosarcoma of the oral and perioral region. J Oral Maxillofac Surg 2013.
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Table 3. CLINICAL DATA OF THE STUDY PATIENTS
PN Age (yr)/Gender
Localization in Head




Initial Treatment in Head
and Neck Region




1 75/M lower lip 0.8 no tumor resection with clear
margins




2 74/F cheek skin 2.5 no tumor resection with clear
margins
no 4.7*
3 39/F trigonum retromolare 1.5 yes tumor resection with clear
margins + cervical LN
dissection + radiation
therapy (49.6 Gy)
masticatory muscles (10 mo); lung,
liver, kidney, bone, adrenal
gland, stomach, thyroid gland
(11 mo)
1.0y
4 73/M hard/soft palate 2 no tumor resection with clear
margins + cervical LN
dissection
pharynx, palate, right masticatory
muscles (7 mo), lung (28 mo)
2.7y
5 25/M floor of mouth 2.5 no tumor resection with clear
margins + cervical LN
dissection
no 6.5*
6 93/F skullcap (metastasis
of pelvic LMS)
4 yes tumor resection with clear
margins
submandibular gland, lung (14mo) 5.3y
7 44/F sinonasal tract (metastasis
of uterine LMS)
NES yes palliative radiation therapy
(56 Gy)
lung (simultaneous) 1.4y
Abbreviations: F, female; LMS, leiomyosarcoma; LN, lymph node; M, male; NES, not elsewhere specified; PN, patient number; T, tumor size at primary diagnosis.
* Alive.
y Died.







































slides displayed a rough, tubercular, and infiltrating
process of growth with fusiform or polygonal cells
(Fig 2A). Both cell forms could be seen regularly.
A cytoplasm seam with a fine fibrillary eosinophilic
texture was always traceable, often with physiologic
mitotic figures. At higher magnification, the tumors
exhibited perpendicularly arranged fascicles of
sharply marginated groups of spindle cells with eo-
sinophilic cytoplasm and characteristic cigar-shaped
nuclei, hyperchromatic blunt-ended nuclei, and scat-
tered paranuclear vacuoles, which constitute the typ-
ical focal histologic features of LMS. Mitotic activity
was found in all tumors (4 to 40 mitoses per 10
high-power fields), and necrosis was present in
all cases. Vascular invasion was only minimally
visible (Fig 2A, B). All lesions had minimal inflamma-
tion that, when present, consisted of scattered lym-
phocytes or lymphoid aggregates. The amount of
collagen fibers between tumor cells was low. Accord-
ing to the National Cancer Institute grading system,21
2 of the 5 primary LMSs of the head and neck region
were assigned to grade 1, 2 to grade 2, and 1
to grade 3.
Immunohistochemically, all tumorswere positive for
vimentin (5 of 5) and ASMA (5 of 5). Two of 3 examined
tumors expressed desmin. In 2 tumors, the prolifera-
tion marker Ki-67 showed positive immunoreactivity.
High magnification disclosed blunt-ended nuclei and
delicate cytoplasmic fibrils, with cells displaying strik-
ing nuclear pleomorphism (Figs 2B, 3A, B). The
FIGURE1. A, En face view of a leiomyosarcoma of the left cheek. B, Radically resected leiomyosarcoma of the left cheek.C, Leiomyosarcoma
at the right side of the floor of the mouth (intraoral tumor mass with necrotic ulcer measuring roughly 3.0 ! 3.0 cm). D, Intraoral view of a leio-
myosarcoma in the right retromolar triangle.
Sch€utz et al. Leimyosarcoma of the oral and perioral region. J Oral Maxillofac Surg 2013.
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proliferation rate of the primary LMS of the lip was
50%, whereas that of the distant metastasis of the
LMS of the uterus was only 5%. Four of 7 tumors
(57%) showed positive immunoreactivity for p16
(Fig 3A), whereas protein p21 expression was signifi-
cantly increased in only 2 cases. The overall expression
of all immunohistochemical markers according to the
LMS location is presented in Table 4.
FIGURE 2. A, Hematoxylin-and-eosin survey view shows a leio-
myosarcoma with a rough trabecular process of growth. B,
Hematoxylin-and-eosin detail view displays microscopic analysis,
which shows intersecting, sharply marginated groups of spindle
cells with eosinophilic cytoplasm, striking nuclear pleomorphism,
and characteristic cigar-shaped nuclei (black arrow). Highly magni-
fied detail view shows moderately increased scattered mitotic activ-
ity (yellow arrow), characteristic cigar-shaped nuclei (black arrow),
and delicate cytoplasmic fibrils.
Sch€utz et al. Leimyosarcoma of the oral and perioral region. J Oral
Maxillofac Surg 2013.
FIGURE 3. Immunohistochemical analysis for expression of pro-
teins p16 and p21 in primary leiomyosarcoma of the head and
neck. A, Diffuse nuclear p16 expression in a leiomyosarcoma
(brown area). Magnified detail view shows diffuse nuclear p16 pos-
itivity (black and yellow arrows). B, No p21 expression.
Sch€utz et al. Leimyosarcoma of the oral and perioral region. J Oral
Maxillofac Surg 2013.
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The average survival period for these patients was
4.3 years (2.7 to 6.5 yr). Lack of p16 was associated
with a shorter average survival period (1.3 vs 4.3 yr
for p16 positivity; Table 4). The 2 patients without re-
currence and metastases showed an expression of p16
(Fig 3A). Five of 7 tumors (71%) were positive for pro-
tein p21. The mean survival period of these p21-
positive patients was 3.8 years (1.0 to 6.5 yr), whereas
the survival period of p21-negative patients was 2.1
years (1.4 to 2.7 yr; Fig 3B). As already mentioned,
the small sample did not allow a statistical calculation
of any correlation. Therefore, the expression of the 2
proteins was not significantly associated with survival.
There was no correlation between protein expression
and localization of the tumor. The analyzed immuno-
histochemical markers p16 and p21 could not be
used to distinguish primary LMSs from distant metasta-
ses originating in the uterus and pelvis.
Discussion
This study analyzed the impact of protein expres-
sion of cell cycle regulators p16 and p21 in primary
and metastatic LMSs of the head and neck region. Be-
cause the latter site is a very uncommon location for
LMS, only a few cases were available for detailed anal-
yses in this series. Therefore, a statistical correlation of
prognosis and tumor localization was not possible.
However, this is the first study that has examined
a small series of primary and metastatic head and
neck LMSs for the expression of proteins p16 and
p21. The 5 patients with a primary LMS showed an av-
erage survival period of 3.3 years (1.0 to 6.5 yr). Of
these, 2 patients survived 4.7 and 6.5 years, respec-
tively (5-yr DSS, 40%). After an average of 17 months,
3 of 5 cases (60%) showed lung metastases. The cur-
rent literature describes a probability of developing
distant metastases of only 35% in primary oral LMS1,2
(Table 1). The lung and liver are predilection sites for
distant metastases of LMS of the head and neck.1,6
In addition to themore frequent distantmetastases of
primary LMS of the head and neck region, in 15% of
cases, metastases can spread to the regional lymph
nodes.2,6,10 In the present study, 1 patient with
primary LMS of the lip developed metastases in the
regional lymph nodes. The local recurrence rate is
approximately 35%2 (Table 1), which is comparable to
the frequencyof recurrence in the present study (43%).
In addition to primary LMS of the head and neck,
secondary lesions can present as distant metastases
from tumors that originate in the female genitalia, espe-
cially the uterus (Table 5).8,23-30 There is obviously a
hematogenous spread from the uterus by the lung to
the oral cavity. Hence, these metastases mainly occur
at highly vascularized areas, such as the masseter
muscle or the tongue. To differentiate primary LMS
from distant metastasis, a thorough preoperative
gynecologic examination combined with whole-body
CTor MRI, as performed in the present cases, is recom-
mended. For further differential diagnosis, additional
positron-emission tomography or CT is reserved for
unclear primary LMSs of the head and neck that show
atypical findings on whole-body CT or MRI scan.
Treatment of primary LMS consists of radical tumor
resection with the goal of histologically clear margins.
This is crucial to determine the true course of the dis-
ease and the long-term prognosis.31-33
Chemotherapy is generally reserved for palliative
cases, such as inoperable primary tumors or metastatic
spread.2,4,10,32 Primary LMSs and distant metastases
are ordinarily resistant to radiation treatment.2,4,5,10
Hence, no remissionwas detected in the present study.
Immunohistochemically, LMSs are usually positive
for desmin, vimentin, and ASMA. These markers are es-
sential for the diagnosis of LMS. Apart from vimentin
and ASMA, the importance and constant overexpres-
sion of desmin could not be confirmed by the present
Table 4. ANALYSIS OF IMMUNOHISTOCHEMICAL STAINING
PN Primary Localization Vimentin Desmin ASMA Ki-67 p16 p21 Follow-Up (yr)
1 lower lip 100% Pos Neg 10% Pos 50% Neg 2% Pos 1.6y
2 skin of cheek Pos Neg Pos NES 2% 5% 4.7*
3 retromolar triangle Pos Pos Pos NES Neg 25% 1.0y
4 palate NES NES NES NES 100% Pos Neg 2.7y
5 floor of mouth Pos Neg Pos NES 5% 5% 6.5*
6 pelvis NES NES NES NES 80% 25% 5.3y
7 uterus 100% Pos 2% Pos 100% Pos 5% Neg Neg 1.4y




Sch€utz et al. Leimyosarcoma of the oral and perioral region. J Oral Maxillofac Surg 2013.
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immunohistochemical data compared with a study by
Montgomery et al4 that found an expression of desmin
in 10 of 12 cases. Although desmin was positive in only
40% of cases in this study, the Ki-67 proliferation rate
was analyzed in 2 cases and showed positive nuclear
staining of 5% and 50%, which is in linewith the results
of other studies of head and neck LMSs.4 Other inves-
tigators have reported a Ki-67 proliferation rate
of 15%.34
Tumor-suppressor protein p16 regulates the cell cy-
cle in the G1 phase by inhibiting the cell proliferation
through the inhibition of cyclin D-dependent kinase
complex 4/6.35 A decreased p16 expression has
been detected in 5% to 33% of LMSs.36,37 A lack of
nuclear p16 expression in neoplastic cells seems to
be associated with progressive tumor size and
decreased overall survival.38 However, there are only
limited data regarding the function and impact of
cell cycle regulator proteins p16 and p21 in mesenchy-
mal neoplasms. Also, the data on p16 and p21 expres-
sions in larger studies of uterine smooth muscle
tumors are incomplete,39-41 so that there are no
comparable results. In the present study, 4 of 7 cases
showed an increased nuclear expression (>25%) of
p16. Although the p16-negative cases had an average
survival period of 1.3 years, the p16-positive cases sur-
vived 4.3 years on average. Although this difference is
not statistically significant because of the small num-
ber of cases, it indicates a worse prognosis when there
is a lack of p16 activity.
Protein p21 is a cyclin kinase inhibitor that is regu-
lated by the tumor suppressor p53. Protein p21 leads
to cell cycle arrest and plays a crucial role in repairing
DNA damage.42,43 Commonly, LMSs express p21,
whereas lack of p21 seems to be associated with an
increased risk of recurrence.44 In the present study,
themean DSS in the p21-negative cases (2.1 yr) was de-
creased compared with the p21-positive cases (3.8 yr).
As in the case of p16, a statement regarding the impact
of p21 expression on DSS and the chance of recur-
rence based on a statistical calculation could not
be made.
Neither p16 nor p21 reactivity could be used to dif-
ferentiate primary LMS from metastasis. Kim et al8 de-
scribed an increased expression of oncogenes for
cellular proliferation and angiogenesis in metastasized
LMS, specifically angiogenin, vascular endothelial
growth factor, CD31, and von Willebrand factor. Al-
though Unver et al45 found that neither p16 nor p21
correlated with disease-free or overall survival in gyne-
cologic LMS, it is generally accepted that p16 is ex-
pressed more frequently and more strongly in LMSs
compared with leiomyomas and is a useful antibody
in discriminating LMSs from leiomyomas.39
Interestingly, the present study showed the influ-
ence of p16 and p21 expression on the long-term prog-
nosis of this disease. To date, there are no other
currently published studies regarding this issue owing
to the rarity of LMS in the head and neck region. Fur-
ther multicenter studies are needed to improve the
treatment and prognosis of this sporadic disease and
to develop more targeted treatments against meta-
static uterine sarcomas.
In conclusion, LMS is an exceedingly rare tumor in
the oral and maxillofacial region and has a poor prog-
nosis because of a high local recurrence rate. There
Table 5. LITERATURE SURVEYOF CLINICAL COURSEOF LEIOMYOSARCOMAWITH DISTANTMETASTASIS IN THE HEAD
AND NECK REGION




Metastasis Treatment Follow-Up (yr)
Allen et al23 (1993) 66 M leg hard palate OP + RT + CT 2y
Allen et al23 (1993) 61 M upper leg mandible OP + RT + CT 3*
Allen et al23 (1993) 65 F uterus lower lip OP + CT 1.4*
Aslan et al24 (2008) 76 F uterus temporal muscle OP ! RT 3*
Bogart et al25 (1990) 58 F lung palate CT + RT 0.4y
Kaziro et al26 (1981) 59 F uterus tongue none unknown
Nusrath et al27 (2006) 65 F uterus masseter muscle OP + CT 2.3y
Sandruck et al28 (2004) 39 F uterus sphenoid OP + CT + RT 1.1y
Uchino et al29 (1996) 54 F uterus skull OP + CT 2y
Kim et al8 (2009) 56 F uterus right maxilla none 0.3y
Vora and Levin30 (2003) 62 F uterus tongue none NESy
Present study 44 F uterus sinonasal tract OP + RT 1.4y
Present study 93 F pelvis skullcap OP + RT 5.3y
Abbreviations: CT, chemotherapy; F, female; M, male; NES, not elsewhere specified; OP, operation; RT, radiation therapy.
* Alive.
y Died.
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may be a predilection for occurrence in the jawbones,
with bone involvement possibly associated with an
even poorer prognosis because of a higher
recurrence rate. In primary LMS, one third of patients
develop distant metastases, with lymph node metasta-
ses being less frequent. Distant metastases in the head
and neck region originating from the female genitalia
must be taken into account in the initial tumor staging;
therefore, whole-body imaging and a gynecologic
examination are necessary.
Aggressive surgical treatment is necessary for a total
cure. Treatment of primary LMS is radical tumor re-
section with histologically clear margins. When
lymph node metastases are suspected, an additional
uni- or bilateral neck dissection is indicated, depend-
ing on the tumor location. Adjuvant radiation and
chemotherapy also may have a beneficial effect in de-
creasing or delaying the recurrence rate, improving
survival time, and sometimes allowing the possibility
of less radical resection.
Immunohistochemical markers such as ASMA and
vimentin are important for the diagnosis of LMS.
They frequently express cyclin kinase inhibitors p16
and p21. Lack of nuclear p16 seems to be associated
with a trend toward a poorer prognosis.
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Leiomyosarkome (LMS) sind sehr seltene Tumoren der glatten Muskulatur, welche am 
häufigsten im Myometrium des Uterus, im Gastrointestinaltrakt und im Retroperitoneum 
auftreten [14]. Insgesamt besitzen sie einen Anteil von etwa 7% an allen 
Weichgewebssarkomen [13]. Weniger als 5% aller Leiomyosarkome manifestieren sich 
im Kopf-Hals-Bereich, weniger als 0,1% treten in der Mundhöhle auf [36]. Nach dem 
Ursprungsgewebe können in der oralen und perioralen Region LMS der oralen 
Weichgewebe, LMS der Gesichtshaut und LMS der Kieferknochen unterschieden 
werden. 
Abzugrenzen von den primären LMS des Kopf-Hals-Bereichs sind sekundäre, 
metastasierte LMS, am häufigsten ausgehend von den weiblichen Genitalien, 
insbesondere vom Uterus [21].  
Aufgrund des seltenen Auftretens der Tumoren im Kopf-Hals-Bereich ist die 
histopathologische Diagnose mitunter schwierig. Immunhistochemische 
Zusatzuntersuchungen, wie etwa die Positivität der Tumoren für Vimentin, Desmin oder 
SMA (Smooth Muscle Actin) sind von entscheidender Bedeutung [34]. Die Proteine p16 
und p21 sind wichtige Regulatoren des Zellzyklus und werden von p53 kontrolliert [8]. 
P53 ist in Leiomyosarkomen häufig mutiert und immunhistochemisch exprimiert [31], 
weshalb ein Zusammenhang der Tumorprogression und dem immunhistochemischen 
Expressionscore von p16 und p21 bestehen könnte. Die Überexpression von p16 scheint 





Die vorliegende retrospektive klinisch-pathologische Studie soll 
1. das charakteristische klinische Erscheinungsbild der LMS des Kopf-Hals-
Bereiches und den Verlauf unter Therapie dokumentieren, 









Die vorliegende klinisch-pathologische Studie umfasst sieben Patienten mit einem 
histopathologisch gesicherten Leiomyosarkom des Kopf-Hals-Bereiches, welche in den 
Jahren 1996 bis 2008 in den Kliniken für Mund-, Kiefer- und Gesichtschirurgie der 
Universität Regensburg und der Universität Lübeck behandelt wurden. Epidemiologische 
Daten, Symptome, Therapie und klinischer Verlauf wurden anhand der ambulanten und 
stationären Patientenakten retrospektiv erhoben. 
Von allen Patienten lagen formalinfixierte, in Paraffin eingebettete Gewebeblöcke vor. 
Zur Analyse wurden gewöhnliche H&E-Färbungen verwandt. Für die 
immunhistochemischen Marker Vimentin, Desmin, ASMA (Alpha Smooth Muscle 
Actin) und Ki67 wurden die Ergebnisse der Routinediagnostik übernommen. Die 
Färbungen für p16 und p21 wurden für alle Tumoren neu angefertigt. Ausgewertet wurde 
hier der prozentuale Anteil an positiv gefärbten Tumorzellen. 
Die Detektion der gebundenen Antikörper erfolgte mit Hilfe des ChemMate 
Detektionssystems (Alkalische Phosphatase) und eines Immunfärbeautomats (Dako 
Autostainer, Deutschland) entsprechend dem Protokoll des Herstellers (Tab. 1). 
Antikörper Klon Hersteller Verdünnung Vorbehandlung 
P16 E6H4 Mtm Laboratories 
Deutschland 
- Peroxidase Blockierungssystem pH 9 
P21 DSC-60.2 Zytomed Systems Deutschland 1:50 Target Retrieval Solution 1:10 pH 6,1 
Vimentin V9 Dako Deutschland 1:4500 Target Retrieval Solution 1:10 pH 9 
Desmin D33 Dako Deutschland 1:200 Target Retrieval Solution 1:10 pH 9 
ASMA 1A4.(1) Dako Deutschland 1:300 Target Retrieval Solution 1:10 pH 9 
Ki67 MIB1 Dako Deutschland 1:1000 Target Retrieval Solution 1:10 pH 6,1 






Das Patientenkollektiv umfasste 3 Männer und 4 Frauen mit einem Durchschnittsalter 
von 60 Jahren (25-93 Jahre), welche an einem LMS des Kopf-Hals-Bereiches erkrankt 
waren. Bei fünf Patienten hatte sich das LMS primär im Kopf-Hals-Bereich entwickelt 
(Tab. 2). 
















Rezidiv / Metastasen 





75/m Unterlippe 0,8 nein Tumorresektion 
lokal R0  
  
Zervikal(3Mo); submandi-
bulär, supraclaviculäre LK, 
Lunge (10 Mo) 
† 1,6   





3 39/w Trigonum 
retromolare 
1,5 ja Tumorresektion 
lokal R0.+ zervikale 
LK-Dissektion + 
Radiatio 49,6 Gy 
Kaumuskulatur (10 Mo) 
Lunge, Leber, Niere, 
Knochen, Nebenniere, 






2 nein Tumorresektion 
local R0 + zervikale 
LK-Dissektion 
Pharynx,, Gaumen, 
Kaumuskulatur re (7 Mo) 
Lunge (28 Mo) 
† 2,7 
5 25/m Mundboden 2,5 nein Tumorresektion 
lokal R0. + zervikale 
LK-Dissektion  
Nein  * 6,5 








Lunge (14 Mo) 
† 5,3 
7 44/w Sinonasaltrakt 
(Metasase 
Uterus-LMS) 




† 1,4  
 
P Patient, a Jahre, m männlich, w weiblich, T Tumorgröße bei Erstdiagnose, n.g. nicht genannt,  
Gy Gray, R0 kein Residualtumor, LK Lymphknoten, † verstorben, * lebend 
 
 






Die Therapie der primären LMS umfasste in beiden Kliniken die Tumorresektion mit 
histologisch tumorfreien Grenzen. Bei drei Patienten wurde eine prophylaktische 
Ausräumung der zervikalen Lymphknoten durchgeführt. In einem Fall erfolgte eine 
postoperative Radiatio. Die LMS-Metastasen im Kopf-Hals-Bereich wurden palliativ 
bestrahlt bzw. reseziert (Tab. 2). 
Drei der fünf Patienten (60%) mit primärem LMS im Kopf-Hals-Bereich entwickelten 
unabhängig von der gewählten Therapie nach durchschnittlich 7 Monaten (3-10) ein 
Tumorrezidiv, nach durchschnittlich 17 Monaten (10-29) zusätzlich Lungenmetastasen. 
Bei einem der beiden Patienten mit solitärer Tumorresektion traten 10 Monate 
postoperativ Metastasen in den Halslymphknoten auf. 
Die LMS des Uterus bzw. Beckens metastasierten in die Keilbeinhöhle und 
Siebbeinzellen bzw. in den Sinus cavernosus, retroaurikulär und in die mediane 
Schädelkalotte und bildeten weitere Tochtergeschwülste in der Lunge und der Glandula 
submandibularis (Tab. 2). 
Von insgesamt 7 Patienten waren zum Ende der Auswertung 5 Patienten nach einem 
durchschnittlichen Überleben von 2,4 Jahren (1,0-5,3) mit stattgefundener 
Fernmetastasierung verstorben. Zwei Patienten mit einem primären LMS der subkutanen 
Wangenhaut bzw. des Mundbodens waren zum Abschluss der Auswertung nach 4,7 bzw. 
6,5 Jahren ohne Hinweis auf ein Rezidiv oder eine Fernmetastasierung am Leben. (Tab. 
2). 
Das durchschnittliche Überleben aller Patienten lag zum Ende der Auswertung bei 3,3 
Jahren (1,0 - 6,5). Die mittlere Überlebensdauer der fünf Patienten mit einem primären 






Die LMS der eigenen Untersuchungsserie zeigten übereinstimmend ein grobknotiges und 
infiltratives Wuchsbild mit spindeligen oder polygonalen Zellen (Abb. 1a und 1b). Beide 
Zellformen waren regelmäßig innerhalb eines Tumors sichtbar. Ein Zytoplasmasaum war 
immer nachweisbar, oft mit feinfibrillärer eosinophiler Textur. Physiologische Mitosen 












Abbildung 1b: HE-Detailaufnhahme: LMS mit spindeligen und runden Tumorzellen; Nachweis einer hohen 




Immunhistochemisch zeigten sich die Tumorzellen positiv für das Intermediärfilament 
Vimentin (5/5) und den Muskelmarker ASMA (5/5). 2 von 5 untersuchten Tumoren 






Desmin ASMA Ki67 p16 p21 Verlauf 
(a) 
1. Unterlippe 100% 
pos 
Neg 10% pos 50% Neg 2% pos † 1,6 
2. Wangenhaut Pos Neg Pos n.d. 2% 5% * 4,7 
3. Trigonum 
retromolare 
Pos Pos Pos n.d. Neg 25% † 1,0 
4 Gaumen n.d. n.d. n.g. n.d. 100% 
pos 
Neg † 2,7 
5. Mundboden Pos Neg Pos n.d. 5% 5% * 6,5 
6. Becken n.d. n.d. n.d. n.d. 80% 25% † 5,3 
7. Uterus 100% 
pos 
2% pos 100% 
pos 
5% Neg Neg † 1,4 
 
P Patient, a Jahre, Pos positive Färbung, Neg negative Färbung, n.d. nicht durchgeführt,† verstorben, * lebend 





Bei zwei Tumoren wurde der Proliferationsmarker Ki-67 bestimmt, wobei das LMS der 
Lippe eine hohe Proliferationrate von 50% aufwies, das primär im Uterus entstandene 
LMS lediglich eine Proliferationsrate von 5% zeigte. 4 von 7 Proben (57%) exprimierten 
nukleäres p16 (Abb. 2a).  
 
 




Für diese Patienten lag das durchschnittliche Überleben bei 4,3 Jahren (2,7-6,5). Die 
Patienten mit Verlust der P16-Expression wiesen hingegen ein durchschnittliches 
Überleben von 1,3 Jahren (1,0-1,6) auf (Tab. 3). Beide Tumoren der rezidiv- und 
metastasenfreien Patienten exprimierten p16. 5 von 7 Tumoren (71%) zeigten sich positiv 
für p21. Hier lag das durchschnittliche Überleben der p21-positiven Fälle bei 3,8 Jahren 






Abbildung 2b: p21 keine Expression 
 
 
Die Expression der beiden Proteine war nicht miteinander assoziiert. Eine Korrelation mit 
der Tumorlokalisation des Primarius konnte nicht beobachtet werden. Ebenso wenig 
ermöglichten die immunhistochemischen Marker eine Differenzieung zwischen primären 







Während Leiomyosarkome sich relativ häufig im Uterus und Gastrointestinatrakt 
manifestieren [12, 25], entstehen primär im Kopf-Hals-Bereich nur 3% aller LMS [28, 
29, 38], da in dieser Region nur wenige glatte Muskelzellen vorliegen. Im Kopf-Hals-
Bereich nehmen LMS vermutlich ihren Ursprung in der Tunika media der Arterien, dem 
Ductus lingualis, den Papillae circumvallatae und den pluripotenten Mesenchymalzellen 
[4, 38]. Der Sinonasal-Trakt (19%), die Haut und das Weichgewebe (16%) sowie der 
Ösophagus (12%) bilden hier die Prädilektionsstellen [38]. 
Angaben zur prognostischen Bedeutung der Lokalisation der primären LMS innerhalb 
des Kopf-Hals-Bereiches sind nicht kongruent. Die aktuelle WHO-Klassifikation der 
Tumoren des Weichgewebes und des Knochens beschreibt eine eher schlechte Prognose 
der primären LMS des Sinonasal-Traktes und eine variable Prognose bei primärem 
Auftreten des LMS im Larynx [16, 33]. Primäre LMS der oralen und perioralen Weich- 
und Hartgewebe zeigen in größeren Untersuchungen eine 5-Jahres-Überlebensrate von 
32-62% [13, 18, 36] (Tab. 4), wobei LMS der oralen Weichgewebe eine bessere 
Prognose aufweisen als LMS der Kieferknochen. Bei den eigenen 5 Patienten mit einem 
primären LMS des Kopf-Hals-Bereiches betrug die mittlere Überlebensdauer 3.3 Jahre 
(1,0-6,5). Lediglich 2 Patienten (5-JÜR ca. 40%) waren nach 4,7 bzw. 6,5 Jahren noch 
am Leben. Eine Zuordnung der Prognose zur Tumorlokalisation konnte aufgrund der 
geringen Fallzahl nicht getroffen werden. In 3 von 5 Fällen (60%) kam es nach 
durchschnittlich 17 Monaten zu einer Fernmetastasierung in Form von 
Lungenmetastasen, was über der in der Literatur angegebenen 
Metastasenwahrscheinlichkeit von etwa 35% für primäre orale LMS liegt [13] (Tab. 4). 
Die Lunge gilt neben der Leber als Prädilektionsstelle für Fernmetastasen beim LMS des 




Neben den häufigeren Fernmetastasierungen kann es bei LMS der Kopf-Hals-Region in 
etwa 15% der Fälle auch zu regionalen Lymphknotenmetastasierungen kommen [11, 13, 
28]. In der eigenen Untersuchungsserie kam es bei einem LMS der Unterlippe zu einer 
Tumorabsiedelung in die Halslymphknoten.  
Bezüglich der Rezidivhäufigket wird für primäre LMS der oralen Weichgewebe eine 
Rezidivrate von etwa 35% angegeben [13] (Tab. 4), was der Rezidivhäufigkeit von 43% 
























Carter et al.   
(1999) [ ] 
11 1,2 :1 40 Kieferknochen (11)  
 
OP (10), RT (3), 
CT (2) 
n.g. 36 † 36% nach 36 
Mo, 
* 36% o T nach 
12 Mo, 
* 18 m T nach 24 
Mo 
Dry et al.  
(2000) [ ] 




OP (9), RT (1), 
CT (2), 
unbekannt (1) 
20 33 † 50% nach 20 
Mo, 
* 40% o.T. nach 
49 Mo 
Ethunandan 
et al.  
(2007) [ ] 
64 1,3: 1 43 Kieferknochen (38), 
Orale Weichgewebe 
(20),  
Gesichtshaut (6)  
OP (60), RT (14), 
CT (11) 
34 35 5-JÜR 55% 
gesamt, 43% bei 
Knocheninfiltrati
on, 19% bei 
Metastasen 
Izumi et al.  
(1995) [ ] 
60 1,4 : 1 42 Kieferknochen (27), 
Sinus maxilaris (14), 
Orale Weichgewebe 
(18), Gesichtshaut (1) 
 
OP (55), RT (4), 
CT (39), 
unbekannt (2)  
44 35 2-JÜR 66%, 5 
JÜR 32% gesamt 
Kratochvil 
et al.   
(1982) [ ] 
20 4:1 65-70 Kieferknochen (8) 
Skelettknochen (12) 
 
OP (18), RT (6), 
CT (2) 
n.g. 37 † 35% nach 24 
Mo,  




y et al. 
 (2002) [ ] 
13 1,2 :1 47 Kieferknochen (5), 
Orale Weichgewebe 





27 55 † 23% nach 67 
Mo,  
* 38% o.T. nach 
50 Mo,  
* 8% m.T. nach 
24 Mo 
31% n.g. 
Vilos et al. 
 (2005) [ ] 
50 1: 1,3 44 Kieferknochen (34), 
Orale Weichgewebe 
(15), Sinus Max. (1)  
OP (46), RT (14), 
CT (13) 
unbekannt (4) 
n.g. 32 5-JÜR 62% 
Eigene 
Studie 
7 1 : 1,3 60 Orale Weichgewebe 
(4), Gesichtshaut (1), 
Metastasen (2) 
 
OP (6), RT (2) 43 71 † 71% nach 29 
Mo  
* 29% o. T. nach 
67 Mo  
 
a Jahr, m männlich, w weiblich, OP Operation, RT Radiatio, CT Chemotherapie, * lebend, † gestorben, o.T. ohne Tumor, m.T. mit 
Tumor, Mo Monate, JÜR Jahresüberlebensrate, n.g. nicht genannt 
 
Tabelle 4: Literaturübersicht zur Epidemiologie, zur Therapie und zum klinischen Verlauf primärer 






Wenn auch selten, so ist bei einem LMS im Kopf-Hals-Bereich dennoch die Möglichkeit 
eines fernmetastasierten Tumors in Erwägung zu ziehen (Tab. 5). Als Primärlokalisation 
zeigt sich hier vor allem der Uterus, was eine präoperative gynäkologische Untersuchung 










Allen et al. 
(1993) [ ] 
66 M Bein Harter Gaumen OP+RT+CT † 2 
Allen et al. 
(1993) [ ] 
61 M Oberschenkel Unterkiefer  OP+RT+CT * 3 
Allen et al. 
(1993) [ ] 
65 W Uterus Unterlippe OP+CT * 1,4 
Aslan et al. 
(2008) [ ] 
76 W Uterus M. temporalis OP-RT * 3 
Bogart et al. 
(1990) [] 
58 W Lunge Gaumen CH+RT † 0,4 
Kaziro et al. 
(1981) [] 
59 W Uterus Zunge Keine Unbekannt 
Nusrath et al. 
(2006) [ ] 
65 W Uterus M.masseter OP+CT † 2,3 
Sandruck et al. 
(2004) [ ] 
39 W Uterus  Sinus 
sphenoidalis 
OP+CT+RT  † 1,1 
Uchino et al. 
(1996) [ ] 
54 W Uterus Schädel OP+CT † 2 
Kim et al. 
(2009) [] 
56 W Uterus Maxilla re Keine † 0,3 
Vora and Levin 
(2003) [] 
62 W Uterus Zunge Keine † n.g. 
Eigene Studie  44  W Uterus Sinonasal Trakt OP+RT † 1,4 
Eigene Studie  93 W Becken Schädelkalotte OP+RT † 5,3 
a Jahre, w weiblich, m männlich, Op Operation, RT Radiatio, CT Chemotherapie, * lebend, † verstorben, M Metastasen, n.g. nicht 
genannt 
 






Als entscheidend für die Prognose gilt bei allen primären LMS die weit im Gesunden 
erfolgte chirurgische Resektion mit histologisch gesicherten, tumorfreien Randschnitten 
[2, 24, 26, 27]. Eine Chemotherapie bleibt üblicherweise palliativen Situationen - wie 
inoperablen Primärtumoren oder bereits erfolgter Metastasierng - vorbehalten [11, 13, 24, 
28]. Gegenüber der Radiatio erweisen sich sowohl primäre LMS als auch LMS-
Metastasen in der Regel als resistent [11, 13, 28, 29]. Auch in der eigenen Studie konnte 
die Radiatio weder beim Primärtumor noch bei den Tumormetastasen eine Remission 
erzielen. 
Die immunhistochemischen Marker ASMA und Vimentin stellen ein wichtiges 
Hilfsmittel zur Diagnose eines Leiomyosarkoms dar, was in der eigenen Untersuchung 
bestätigt werden konnte. Hingegen zeigte sich Desmin nur in 40% der Fälle als positiv. 
Die Ki67-Proliferationsrate wurde nur in 2 Fällen untersucht (5% und 50%). In der Regel 
liegt die Zellproliferationsrate von LMS bei über 15% [34]. 
Das Tumor-Suppressor-Protein p16 reguliert den Zellzyklus in der G1-Phase, indem es 
den Cyclin D-abhängigen Kinasekomplex 4/6 und somit die Zellproliferation hemmt 
[23]. Eine verringerte p16-Expression wurde in 5-33% von LMS beobachtet [9, 17]. 
Verlust an nukleärer P16-Expression in neoplastischen Zellen scheint beim LMS der 
Weichgewebe mit fortgeschrittener Tumorgröße und schlechterem Gesamtüberleben 
assoziiert [19].  
In der eigenen Untersuchung zeigte sich in 4 von 7 Fällen eine nukleäre Expression von 
p16. Während die p16-negativen Fälle ein durchschnittliches Überleben von 1,3 Jahren 
aufwiesen, lag das durchschnittliche Überleben der p16-positiven Fälle bei 4,3 Jahren, 
was auf eine Prognoseverschlechterung durch p16-Verlust hindeutet. 
Bei p21 handelt es sich ebenfalls um ein Cyclin-Kinase-Inhibitor-Protein. Reguliert durch 




Funktion bei der Reparatur von DNA-Schäden [1, 39].  Leiomyosarkome der 
Weichgewebe exprimieren üblicherweise p21, wobei der Verlust der p21-Expression mit 
einem erhöhten Rezidivrisiko einherzugehen scheint [10]. Zwar lag auch in der 
vorliegenden Studie das durchschnittliche Gesamtüberleben der p21-negativen Fälle (2,1 
Jahre) im Vergleich zu den p21-positiven Fällen (3,8 Jahre) niedriger, eine prognostische 
Aussage bezüglich Rezidiv- oder Gesamtüberlebenswahrscheinlichkeit lässt hier jedoch 
nicht treffen. Eine Differenzierung zwischen primären LMS und LMS-Metastasen war 
weder durch p16 noch durch p21 erkennbar. Kim et al. beschreiben in den metastasierten 
LMS eine erhöhte Expression an Onkogenen für die zelluläre Proliferation und die 




1. Primäre Leiomyosarkome des Kopf-Hals-Bereiches lassen Fernmetastasen, v.a. in die 
Lunge, bei jedem dritten Patienten erwarten. Regionäre Lymphknotenmetastasen sind 
seltener, können aber ebenfalls auftreten. In Betracht zu ziehen ist immer die 
Metastasierung eines LMS in den Kopf-Hals-Bereich. Als Primarius findet sich hier 
häufig der Uterus. Ein umfassendes präoperatives Ganzkörper-Staging inklusive 
gynäkologischer Abklärung ist daher zu empfehlen.  
2. Die Therapie von LMS im Kopf-Hals-Bereich besteht in der radikalen chirurgischen 
Entfernung des Tumors. Bei Verdacht auf Lymphknotenmetastasen sollten diese mit 
exstirpiert werden. Die Strahlentherapie scheint hingegen keinen großen therapeutischen 
Wert zu besitzen. 




eins Leiomyosarkoms. LMS exprimieren häufig die Cyclinkinase-Inhibitoren p16 und 
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